Epidemiology and costs of depressive disorder in Spain: the EPICO study
- PMID: 34058711
- DOI: 10.1016/j.euroneuro.2021.04.022
Epidemiology and costs of depressive disorder in Spain: the EPICO study
Abstract
Depressive Disorders are the most common psychiatric diagnoses in the general population. To estimate the frequency, costs associated with Depressive Disorders in usual clinical practice, and in the whole Spanish population, a longitudinal, retrospective, observational study was carried out using data from the BIG-PAC database®. Study population: all patients aged ≥ 18 years with a diagnosis of a Depressive Disorder in 2015-2017. Prevalence was computed as the proportion of Depressive Disorder cases in the adult general population, and the incidence rate, as the number of new Depressive Disorder cases diagnosed per 1,000 person-years in the population using health services, during 2015-2017. We collected demographic variables, comorbidity, direct health costs, and indirect costs (temporary and permanent disability). Health costs related to Depressive Disorders were estimated according to the annual resource use rate (resource/patient/year). Indirect costs were calculated according to the human capital method. Using the study data and information from the Spanish National Institute of Statistics, we estimated the cost of Depressive Disorders corresponding to the Spanish adult population, including premature mortality. 69,217 Depressive Disorder patients aged ≥ 18 years who met the inclusion/exclusion criteria were studied (mean age: 56.8 years; female: 71.4%). Prevalence of Depressive Disorders in the general population was 4.73% (95% CI: 4.70-4.76%). Annual incidence rates (2015-2017) were 7.12, 7.35 and 8.02 per 1,000 person-years, respectively. Total costs observed in our Depressive Disorder patients were € 223.9 million (corresponding to a mean of € 3,235.3; mean/patient/year), of which, 18.4% were direct health care costs and 81.6%, non-health indirect costs (18% temporary occupational disability, 63.6% permanent disability). Considering also the cost of premature death, the mean cost per patient/year was € 3,402 and the estimated societal costs of Depressive Disorders in Spain were € 6,145 million. The prevalence and incidence of Depressive Disorders are consistent with other series reviewed. Resource use and total costs (especially non-health costs) were high.
Keywords: Depressive disorder; Epidemiology; Health costs; Non-health costs.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest TH and BH are full-time employees of Janssen-Cilag S.A. ASM and ASN are independent consultants at Atrys Health regarding the development of this study. EV has received grants and served as consultant, advisor or CME speaker unrelated to the present work for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, GH Research, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion, and Takeda. VP has been a consultant to or has received honoraria or grants from AB-Biotics, AstraZeneca, Bristol-Myers-Squibb, CIBERSAM, FIS- ISCiii, Janssen Cilag, Lundbeck, Otsuka, Servier and Pfizer. MR has received grants or served as advisor or speaker unrelated to the present work for Janssen, Lundbeck and Pfizer.
Similar articles
-
Costs of depression in Catalonia (Spain).J Affect Disord. 2011 Jul;132(1-2):130-8. doi: 10.1016/j.jad.2011.02.019. Epub 2011 Mar 12. J Affect Disord. 2011. PMID: 21402411
-
Smoking Status and Cost of Illness in Patients with Depressive Disorder Based on the National Health Survey in Spain.Subst Use Misuse. 2019;54(5):713-723. doi: 10.1080/10826084.2018.1536717. Epub 2018 Dec 26. Subst Use Misuse. 2019. PMID: 30585110
-
Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.Pharmacoeconomics. 2008;26(1):57-73. doi: 10.2165/00019053-200826010-00006. Pharmacoeconomics. 2008. PMID: 18088159
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
[Diabetes mellitus in Spain: death rates, prevalence, impact, costs and inequalities].Gac Sanit. 2006 Mar;20 Suppl 1:15-24. doi: 10.1157/13086022. Gac Sanit. 2006. PMID: 16539961 Review. Spanish.
Cited by
-
A GBD 2019 study of health and Sustainable Development Goal gains and forecasts to 2030 in Spain.Sci Rep. 2022 Dec 7;12(1):21154. doi: 10.1038/s41598-022-24719-z. Sci Rep. 2022. PMID: 36477107 Free PMC article.
-
Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use.Clin Psychopharmacol Neurosci. 2024 Feb 29;22(1):159-168. doi: 10.9758/cpn.23.1097. Epub 2023 Sep 6. Clin Psychopharmacol Neurosci. 2024. PMID: 38247422 Free PMC article.
-
A Cross-Sectional Study on the Associations between Physical Activity Level, Depression, and Anxiety in Smokers and Ex-Smokers.Healthcare (Basel). 2022 Jul 27;10(8):1403. doi: 10.3390/healthcare10081403. Healthcare (Basel). 2022. PMID: 36011059 Free PMC article.
-
Exploring depression in adults over a decade: a review of longitudinal studies.BMC Psychiatry. 2025 Apr 15;25(1):378. doi: 10.1186/s12888-025-06828-x. BMC Psychiatry. 2025. PMID: 40234864 Free PMC article.
-
Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?Medicina (Kaunas). 2023 Jul 3;59(7):1240. doi: 10.3390/medicina59071240. Medicina (Kaunas). 2023. PMID: 37512053 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous